Your session is about to expire
← Back to Search
Speech Entrainment for Aphasia
N/A
Recruiting
Led By Marja-Liisa Mailend, PhD
Research Sponsored by Albert Einstein Healthcare Network
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Between 18-80 years at the time of enrollment
English as native language
Must not have
History of other comorbid neurological impairments
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one day post treatment
Awards & highlights
No Placebo-Only Group
Summary
This trial looks at how speech entrainment can help people speak more efficiently and effectively. It tracks informativeness and efficiency of speech to measure outcomes.
Who is the study for?
This trial is for English-speaking adults aged 18-80 with aphasia, which affects their ability to communicate. They must be more than six months post-onset and have a specific score on the Western Aphasia Battery - Revised test. Participants need to commit to multiple sessions either at the testing site or at home.
What is being tested?
The study tests two types of speech entrainment practices: audiovisual and auditory, to improve independent speech in people with aphasia. It measures how informative and efficient their speech is after treatment when telling stories.
What are the potential side effects?
Since this trial involves practice-based interventions rather than medication, traditional side effects are not expected. However, participants may experience fatigue or frustration during the exercises.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 18 and 80 years old.
Select...
English is my first language.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have a history of neurological problems.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ one day post treatment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one day post treatment
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Correct Information Units per Minute
Secondary study objectives
Number of Different Words per Minute
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Auditory Speech Entrainment PracticeExperimental Treatment2 Interventions
Auditory Speech Entrainment includes repeated practice of speaking synchronously with a recorded model, which provides contextual, temporal, and auditory cues for speaking.
Group II: Audiovisual Speech Entrainment PracticeExperimental Treatment2 Interventions
Audiovisual Speech Entrainment includes repeated practice of speaking synchronously with a recorded model, which provides contextual, temporal, and audiovisual cues for speaking.
Find a Location
Who is running the clinical trial?
National Institute on Deafness and Other Communication Disorders (NIDCD)NIH
361 Previous Clinical Trials
182,257 Total Patients Enrolled
Albert Einstein Healthcare NetworkLead Sponsor
64 Previous Clinical Trials
868,669 Total Patients Enrolled
Marja-Liisa Mailend, PhDPrincipal InvestigatorAlbert Einstein Healthcare Network
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am between 18 and 80 years old.More than six months since symptoms started.You have a history of struggling with learning.English is my first language.You have difficulty speaking and understanding language.I am willing and able to follow through with multiple testing sessions.I have a history of neurological problems.You have been diagnosed with aphasia using the Western Aphasia Battery - Revised (WAB-R).
Research Study Groups:
This trial has the following groups:- Group 1: Auditory Speech Entrainment Practice
- Group 2: Audiovisual Speech Entrainment Practice
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.